FDA approves J&J’s Concerta for treatment of ADHD in adults
The FDA approval was based on clinical trial data in adults ages 18 to 65. In these studies, use of Concerta was shown to significantly improve ADHD symptoms
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).